Response to Du et al, “Beyond gastrointestinal symptom burden: Integrating fecal calprotectin into a multimodal safety strategy before initiating bimekizumab in hidradenitis suppurativa”
Response to Du et al, “Beyond gastrointestinal symptom burden: Integrating fecal calprotectin into a multimodal safety strategy before initiating bimekizumab in hidradenitis suppurativa”. // Journal of the American Academy of Dermatology. – URL: https://www.sciencedirect.com/science/article/pii/S0190962226032883?dgcid=rss_sd_all
Response to Du et al, “Beyond gastrointestinal symptom burden: Integrating fecal calprotectin into a multimodal safety strategy before initiating bimekizumab in hidradenitis suppurativa”. Journal of the American Academy of Dermatology. https://www.sciencedirect.com/science/article/pii/S0190962226032883?dgcid=rss_sd_all
“Response to Du et al, “Beyond gastrointestinal symptom burden: Integrating fecal calprotectin into a multimodal safety strategy before initiating bimekizumab in hidradenitis suppurativa”.” Journal of the American Academy of Dermatology.
@article{article119095,
title = {Response to Du et al, “Beyond gastrointestinal symptom burden: Integrating fecal calprotectin into a multimodal safety strategy before initiating bimekizumab in hidradenitis suppurativa”},
journal = {Journal of the American Academy of Dermatology},
url = {https://www.sciencedirect.com/science/article/pii/S0190962226032883?dgcid=rss_sd_all}
}